HEMORRHAGING FOCAL ENCEPHALITIS UNDER FINGOLIMOD (FTY720) TREATMENT: A CASE REPORT

@article{Leypoldt2009HEMORRHAGINGFE,
  title={HEMORRHAGING FOCAL ENCEPHALITIS UNDER FINGOLIMOD (FTY720) TREATMENT: A CASE REPORT},
  author={Frank Leypoldt and Alexander M{\"u}nchau and Friederike Moeller and Maxim Bester and Christian Gerloff and Christoph Heesen},
  journal={Neurology},
  year={2009},
  volume={72},
  pages={1022 - 1024}
}
Several new treatments for relapsing-remitting multiple sclerosis (RRMS) are currently being tested in phase III clinical trials. Fingolimod (FTY720) is an oral sphingosine 1 phosphate receptor (SP1PR) agonist inhibiting lymphocyte egress from lymph nodes.1,2 Fingolimod has shown efficacy in experimental autoimmune encephalitis3 and during phase II testing in RRMS.4 An orally available and well-tolerated drug would be a milestone in MS treatment. Known side effects are upper respiratory tract… 

Figures from this paper

Tumefactive multiple sclerosis lesions under fingolimod treatment

Fingolimod is an oral sphingosine 1-phosphate receptor modulator that prevents recirculation of lymphocyte subsets from lymph nodes. It decreases the number of relapses, slows the progression of

Primary varicella zoster infection associated with fingolimod treatment

The oral drug sphingosine-1-phosphate-receptor modulator, fingolimod (FTY720), has been recently shown to have superior efficacy vs IM interferon-β 1a on clinical and MRI outcomes (TRANSFORMS study), however, 2 fatal viral infections occurred in patients who received fingolIMod, including one case of primary varicella zoster.

Neurological safety of fingolimod: An updated review

Since the approval of FTY for RRMS in Japan in 2011, it has been administered to approximately 5000 MS patients, and there have been side‐effect reports from 1750 patients, which included infectious diseases, hepatobiliary disorders, nervous system disorders and cardiac disorders.

Overview and safety of fingolimod hydrochloride use in patients with multiple sclerosis

Fingolimod is an effective treatment for relapsing MS and its oral route of administration may be preferred by some, and it is generally well tolerated but requires diligence in patient selection and monitoring.

CRITICAL VASOSPASM DURING FINGOLIMOD (FTY720) TREATMENT IN A PATIENT WITH MULTIPLE SCLEROSIS

We report on a woman who developed critical arterial vasospasm of the left arm within 7 days after having started treatment with Fingolimod (FTY720). Fingolimod is an orally administered modulator of

Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment.

Two aspects relevant to any newly approved multiple sclerosis treatment with immunomodulatory properties are highlighted with this case: possible rebound of disease activity after discontinuation; second, the occurrence of a tumor as a possible treatment-related complication.

Tumefactive demyelination and a malignant course in an MS patient during and following fingolimod therapy

Multiple sclerosis treatment with fingolimod: profile of non-cardiologic adverse events

The present review lists the non-cardiologic adverse events that all neurologists prescribing fingolimod should be aware of, and its first hours of use are associated with related to S1P receptors in the heart.

Severe aseptic temporal lobe encephalitis on fingolimod.

Advances in the treatment of relapsing—remitting multiple sclerosis — critical appraisal of fingolimod

This review focuses on advances in current and novel oral treatment approaches in MS, focusing on the recent development, approval, and the clinical experience with fingolimod.
...

References

SHOWING 1-7 OF 7 REFERENCES

Oral fingolimod (FTY720) for relapsing multiple sclerosis.

In this proof-of-concept study, fingolimod reduced the number of lesions detected on MRI and clinical disease activity in patients with multiple sclerosis and both measures decreased in patients who switched from placebo to fingolIMod.

Physiologically Based Pharmacokinetic Modeling of FTY720 (2-Amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in Rats After Oral and Intravenous Doses

A physiologically based pharmacokinetic model was developed to predict the concentration of FTY720 in various organs of the body and good agreement was found between the actual and predicted blood concentration-time profiles, including brain concentrations in dogs and humans.

Finding a way out: lymphocyte egress from lymphoid organs

The body of evidence supporting a model in which lymphocyte egress is promoted by encounter with S1P at exit sites is discussed, and work examining the effects of S 1P receptor agonists on endothelium is related.